Recent Advances of Acute Kidney Injury in Hematopoietic Cell Transplantation

dc.contributor.authorMiyata, Masahiro
dc.contributor.authorIchikawa, Kazunobu
dc.contributor.authorMatsuki, Eri
dc.contributor.authorWatanabe, Masafumi
dc.contributor.authorPeltier, Daniel
dc.contributor.authorToubai, Tomomi
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2024-10-24T11:40:49Z
dc.date.available2024-10-24T11:40:49Z
dc.date.issued2022-01-04
dc.description.abstractAcute kidney injury (AKI) is a common complication of allogeneic hematopoietic cell transplantation (allo-HCT) and is associated with non-relapse mortality (NRM) and quality of life (QOL). Multiple factors may contribute to AKI during allo-HCT and are often present at the same time making it difficult to determine the cause of AKI in each patient. Nephrotoxic drugs, infections, thrombotic microangiopathy (TMA), and sinusoidal obstruction syndrome (SOS) are well described causes of AKI during allo-HCT. Acute graft-versus-host disease (aGVHD) is a major complication of allo-HCT that mainly targets the intestines, liver, and skin. However, recent studies suggest aGVHD may also attack the kidney and contribute to AKI following allo-HCT. For example, severe aGVHD is associated with AKI, suggesting a link between the two. In addition, animal models have shown donor immune cell infiltration and increased expression of inflammatory cytokines in recipient kidneys after allo-HCT. Therefore, aGVHD may also target the kidney and contribute to AKI following allo-HCT. Herein, we describe the etiology, diagnosis, risk factors, pathophysiology, prevention, and treatment of renal injury after allo-HCT. In addition, we highlight emerging evidence that aGVHD may contribute to the development of AKI after allo-HCT.
dc.eprint.versionFinal published version
dc.identifier.citationMiyata M, Ichikawa K, Matsuki E, Watanabe M, Peltier D, Toubai T. Recent Advances of Acute Kidney Injury in Hematopoietic Cell Transplantation. Front Immunol. 2022;12:779881. Published 2022 Jan 4. doi:10.3389/fimmu.2021.779881
dc.identifier.urihttps://hdl.handle.net/1805/44191
dc.language.isoen_US
dc.publisherFrontiers Media
dc.relation.isversionof10.3389/fimmu.2021.779881
dc.relation.journalFrontiers in Immunology
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcePMC
dc.subjectAcute kidney injury
dc.subjectAllogeneic hematologic stem cell transplantation
dc.subjectGvHD
dc.subjectExperimental BMT
dc.subjectCytokine
dc.subjectCalcinurin inhibitors
dc.subjectThrombotic microagiopathy
dc.titleRecent Advances of Acute Kidney Injury in Hematopoietic Cell Transplantation
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Miyata2022Recent-CCBY.pdf
Size:
822.64 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: